<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03856216</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0860</org_study_id>
    <secondary_id>NCI-2019-00531</secondary_id>
    <secondary_id>2018-0860</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT03856216</nct_id>
  </id_info>
  <brief_title>Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation</brief_title>
  <official_title>Addition of Inotuzumab Ozogamicin Pre- and Post-Allogeneic Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this phase II clinical study is to learn about the safety of inotuzumab
      ozogamicin when given with fludarabine, with or without bendamustine, melphalan, and
      rituximab before and after a stem cell transplant. Researchers also want to learn if
      inotuzumab ozogamicin when given after a stem cell transplant can help control leukemia and
      lymphoma. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a
      chemotherapy drug called ozogamicin. Inotuzumab attaches to CD22-positive cancer cells in a
      targeted way and delivers ozogamicin to kill them. Giving chemotherapy before a bone marrow
      or peripheral blood stem cell transplant helps stop the growth of cells in the bone marrow,
      including normal blood-forming cells (stem cells) and cancer cells. Sometimes the
      transplanted cells from a donor attack the body's normal cells (called graft-versus-host
      disease). Giving tacrolimus and filgrastim before or after the transplant may stop this from
      happening. Fludarabine, bendamustine, melphalan, and rituximab are commonly given before stem
      cell transplants. Giving inotuzumab ozogamicin with chemotherapy may work better in treating
      patients with leukemia or lymphoma undergoing stem cell transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To assess the safety of the addition of inotuzumab ozogamicin (IO) pre- and
      post-allogeneic transplantation in patients with CD22-positive hematological malignancies.

      SECONDARY OBJECTIVES:

      I. Overall survival, progression-free survival and relapse rates. II. Treatment-related
      mortality. III. Cumulative incidence of acute and chronic graft-versus-host disease (GVHD).

      OUTLINE: Patients are assigned to 1 of 2 groups.

      GROUP I: Patients with acute lymphoblastic leukemia (ALL) receive inotuzumab ozogamicin
      intravenously (IV) over 1 hour on day -13, fludarabine IV over 1 hour on days -5 to -2,
      melphalan IV over 30 minutes on day -2, and tacrolimus IV continuously beginning on day -2
      then orally (PO) once daily (QD) or twice daily (BID) for about 6 months. Patients receiving
      stem cells from a matched unrelated donor (MUD), receive anti-thymocyte globulin IV over 3-4
      hours on days -2 to -1 and not receive chemotherapy drugs. Patients also receive bone marrow
      or peripheral blood progenitor cells IV on day 0. Patients then receive methotrexate IV over
      30 minutes on days 1, 3, 6, and 11 and filgrastim-sndz subcutaneously (SC) QD beginning 1
      week after the transplant until blood cell levels return to normal. Patients with
      CD22-positive cancer, receive rituximab IV over 4-6 hours on days 1 and 8.

      GROUP II: Patients with lymphoma receive inotuzumab ozogamicin IV over 1 hour on day -13,
      fludarabine IV over 1 hour and bendamustine IV over 30 minutes to 1 hour on days -5 to -3,
      and tacrolimus IV continuously beginning on day -2 then PO QD or BID for about 6 months.
      Patients receiving stem cells from a MUD, receive anti-thymocyte globulin IV over 3-4 hours
      on days -2 to -1 and not receive chemotherapy drugs. Patients also receive bone marrow or
      peripheral blood progenitor cells IV on day 0. Patients then receive rituximab IV over 4-6
      hours on days 1 and 8, methotrexate IV over 30 minutes on days 1, 3, and 6, and
      filgrastim-sndz SC once a day beginning 1 week after the transplant. Patients who received a
      stem cell transplant from a MUD also receive methotrexate IV over 30 minutes on day 11.

      MAINTENANCE: Between 45 and 100 days after stem cell transplantation, all patients receive
      inotuzumab ozogamicin IV over 1 hour on days 1 and 2. Beginning 28 to 100 days after start of
      first cycle, patients receive inotuzumab ozogamicin IV over 1 hour on days 1 and 2 in the
      absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up periodically.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of grade 3 or higher renal, hepatic, cardiac, pulmonary, or neurologic toxicity</measure>
    <time_frame>Up to 30 days after cycle 1 of maintenance therapy</time_frame>
    <description>Will be assessed using the Bayesian method of Thall, Simon, and Estey. At the end of the trial, the rates of severe toxicity will be summarized, and analyses will be performed to assess the relationship between each toxicity endpoint and covariates of interest using logistic regression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-related mortality (TRM)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The cumulative incidence of TRM will be assessed in a competing risks framework with the competing risk of disease relapse. Regression models will be fit to assess the relationship between each and covariates of interest using the method of Fine and Gray.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The distribution of OS will be assessed using the Kaplan-Meier method, and distributions will be compared using the log-rank test. Cox proportional hazards regression models will be fit to assess the relationship between OS and covariates of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The distribution of PFS will be assessed using the Kaplan-Meier method, and distributions will be compared using the log-rank test. Cox proportional hazards regression models will be fit to assess the relationship between PFS and covariates of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute graft versus host disease (GVHD)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The cumulative incidence of acute GvHD will be assessed in a competing risks framework with competing risks of death without relapse and disease relapse. The method of Fine and Gray will be used to assess the association between GvHD and covariates of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic GVHD</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The cumulative incidence of chronic GvHD will be assessed in a competing risks framework with competing risks of death without relapse and disease relapse. The method of Fine and Gray will be used to assess the association between GvHD and covariates of interest.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>B Acute Lymphoblastic Leukemia</condition>
  <condition>Lymphocytic Neoplasm</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Group I (inotuzumab ozogamicin, chemotherapy, transplant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (inotuzumab ozogamicin, chemotherapy, transplant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Bone Marrow Transplantation</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (inotuzumab ozogamicin, chemotherapy, transplant)</arm_group_label>
    <arm_group_label>Group II (inotuzumab ozogamicin, chemotherapy, transplant)</arm_group_label>
    <other_name>Allo BMT</other_name>
    <other_name>Allogeneic Blood and Marrow Transplantation</other_name>
    <other_name>Allogeneic BMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-Thymocyte Globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (inotuzumab ozogamicin, chemotherapy, transplant)</arm_group_label>
    <arm_group_label>Group II (inotuzumab ozogamicin, chemotherapy, transplant)</arm_group_label>
    <other_name>Antithymocyte Globulin</other_name>
    <other_name>Antithymocyte Serum</other_name>
    <other_name>ATG</other_name>
    <other_name>ATS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group II (inotuzumab ozogamicin, chemotherapy, transplant)</arm_group_label>
    <other_name>SDX-105</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim-sndz</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (inotuzumab ozogamicin, chemotherapy, transplant)</arm_group_label>
    <arm_group_label>Group II (inotuzumab ozogamicin, chemotherapy, transplant)</arm_group_label>
    <other_name>Filgrastim Biosimilar Filgrastim-sndz</other_name>
    <other_name>Zarxio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (inotuzumab ozogamicin, chemotherapy, transplant)</arm_group_label>
    <arm_group_label>Group II (inotuzumab ozogamicin, chemotherapy, transplant)</arm_group_label>
    <other_name>Fluradosa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inotuzumab Ozogamicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (inotuzumab ozogamicin, chemotherapy, transplant)</arm_group_label>
    <arm_group_label>Group II (inotuzumab ozogamicin, chemotherapy, transplant)</arm_group_label>
    <other_name>Besponsa</other_name>
    <other_name>CMC-544</other_name>
    <other_name>Way 207294</other_name>
    <other_name>WAY-207294</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (inotuzumab ozogamicin, chemotherapy, transplant)</arm_group_label>
    <other_name>Alanine Nitrogen Mustard</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine Mustard</other_name>
    <other_name>L-Sarcolysin</other_name>
    <other_name>L-Sarcolysin Phenylalanine mustard</other_name>
    <other_name>L-Sarcolysine</other_name>
    <other_name>Melphalanum</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine Nitrogen Mustard</other_name>
    <other_name>Sarcoclorin</other_name>
    <other_name>Sarkolysin</other_name>
    <other_name>WR-19813</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (inotuzumab ozogamicin, chemotherapy, transplant)</arm_group_label>
    <arm_group_label>Group II (inotuzumab ozogamicin, chemotherapy, transplant)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (inotuzumab ozogamicin, chemotherapy, transplant)</arm_group_label>
    <arm_group_label>Group II (inotuzumab ozogamicin, chemotherapy, transplant)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSCT</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplant</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (inotuzumab ozogamicin, chemotherapy, transplant)</arm_group_label>
    <arm_group_label>Group II (inotuzumab ozogamicin, chemotherapy, transplant)</arm_group_label>
    <other_name>ABP 798</other_name>
    <other_name>BI 695500</other_name>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>CT-P10</other_name>
    <other_name>IDEC-102</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 Monoclonal Antibody</other_name>
    <other_name>MabThera</other_name>
    <other_name>Monoclonal Antibody IDEC-C2B8</other_name>
    <other_name>PF-05280586</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Rituximab ABBS</other_name>
    <other_name>Rituximab Biosimilar ABP 798</other_name>
    <other_name>Rituximab Biosimilar BI 695500</other_name>
    <other_name>Rituximab Biosimilar CT-P10</other_name>
    <other_name>Rituximab Biosimilar GB241</other_name>
    <other_name>Rituximab Biosimilar IBI301</other_name>
    <other_name>Rituximab Biosimilar JHL1101</other_name>
    <other_name>Rituximab Biosimilar PF-05280586</other_name>
    <other_name>Rituximab Biosimilar RTXM83</other_name>
    <other_name>Rituximab Biosimilar SAIT101</other_name>
    <other_name>rituximab biosimilar TQB2303</other_name>
    <other_name>rituximab-abbs</other_name>
    <other_name>RTXM83</other_name>
    <other_name>Truxima</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV and PO</description>
    <arm_group_label>Group I (inotuzumab ozogamicin, chemotherapy, transplant)</arm_group_label>
    <arm_group_label>Group II (inotuzumab ozogamicin, chemotherapy, transplant)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Young adults (age 18-35) with ALL will be included only if they are not eligible for
             myeloablative transplants.

          -  CD22+ lymphoid malignancies including B acute lymphoblastic leukemia (B-ALL).

          -  Eligible to receive a reduced-intensity allogeneic hematopoietic stem cell
             transplantation (alloSCT).

          -  Donor: HLA compatible related or matched unrelated donor (HLA-A, B, C, DRB1).

          -  Performance status of 0 to 2.

          -  Creatinine less than or equal to 1.6 mg/dL (at time of study entry).

          -  Bilirubin less than 1.6 mg/dL (at time of study entry).

          -  Serum glutamate pyruvate transaminase (SGPT) &lt; 2 x upper limit of normal (ULN) (at
             time of study entry).

          -  Ejection fraction &gt;= 40% (at time of study entry).

          -  Forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and
             diffusion capacity of the lung for carbon monoxide (DLCO) &gt;= 40% (at time of study
             entry).

          -  Negative beta human chorionic gonadotropin (HCG) test in a woman with child bearing
             potential defined as not post-menopausal for 12 months or no previous surgical
             sterilization) or currently breast-feeding. Pregnancy testing is not required for post
             menopausal or surgically sterilized women.

        Exclusion Criteria:

          -  Human immunodeficiency virus (HIV) positive.

          -  Philadelphia chromosome (Ph)-positive ALL.

          -  Active and uncontrolled disease/infection.

          -  Unable or unwilling to sign consent.

          -  Current active hepatic or biliary disease (with exception of Gilbert's syndrome).

          -  Active hepatitis B or C.

          -  Recent chemotherapy or radiation within 3 weeks of study entry. Exception: ibrutinib
             and venetoclax are allowed to within 3 days.

          -  Prior inotuzumab ozogamicin within 3 weeks of study entry.

          -  Peripheral blast count of greater than 10 K/microL.

          -  Corrected QT using Fridericia's formula (QTcF) interval &gt; 470 ms.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Issa F Khouri</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Issa F Khouri</last_name>
    <phone>713-792-8750</phone>
    <email>ikhouri@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Issa F. Khouri</last_name>
      <phone>713-745-0049</phone>
      <email>ikhouri@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Issa F. Khouri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>February 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2019</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
    <mesh_term>Inotuzumab Ozogamicin</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

